Conditions: Rhinitis, Allergic, Seasonal
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 201
Healthy volunteers: no

Brief summary:
This study investigated the onset of symptom relief following initiation of treatment with mometasone furoate (MK-0887/SCH 032088) 200 mcg administered once daily compared with placebo for 14 days.

Detailed description:

Arms:
arm 1: Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days. arm 2: Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.

Interventions: intervention 1: mometasone furoate nasal spray intervention 2: placebo nasal spray
Intervention descriptions: intervention 1: intranasal administration intervention 2: intranasal administration

Protocol document: